Drug guards against rise in Alzheimer’s proteins from air pollution, study shows
By
Kristen Fischer
Aug 12, 2024
A drug protected mice from increases in Alzheimer’s-related proteins when the animals were exposed to air pollution, a new study showed. Researchers hope the results may be the same in humans one day.
Clinical briefs for Friday, Feb. 18
By
Amy Novotney
Feb 18, 2022
CDC reforming COVID-19 guidance … Nearly three-quarters of the U.S. now estimated to be immune to omicron variant … Brain synapse destruction culprit behind Alzheimer’s cognitive decline … Treatment...
Alzheimer’s drug slows mental, functional decline in Eli Lilly trial
By
Alicia Lasek
Jan 12, 2021
Participants who took donanemab for 76 weeks showed 32% slower decline in thinking and daily function compared with those in a placebo group.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
Drug that targets Alzheimer’s inflammation approved for trial by FDA
By
Alicia Lasek
Feb 09, 2021
An experimental drug meant to treat the “type 3 diabetes” that some scientists believe triggers Alzheimer’s has been approved for a late-stage clinical trial.
Researchers receive $47M grant to study Alzheimer’s disease
By
John Roszkowski
Sep 26, 2022
Researchers from the University of California, Irvine have been awarded a $47 million grant from the National Institute on Aging to develop animal models to study the biology behind Alzheimer’s disease.
Study: Having two copies of gene mutation linked to Alzheimer’s may cause onset
By
Kristen Fischer
May 07, 2024
A new study finds that possessing two copies of a specific gene mutation that’s common in Alzheimer’s disease may be the cause behind the disease in those people.
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...